The following are recent financial reports as posted by selected Utah corporations:
Sera Prognostics
Sera Prognostics Inc., based in Salt Lake City, reported a net loss of $8 million, or 16 cents per share, for the second quarter ended June 30. That compares with a loss of $8.3 million, or 25 cents per share, for the same quarter a year earlier.
Revenue in the most recent quarter totaled $17,000, down from $24,000 in the year-earlier quarter.
Sera Prognostics is a health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care.
“We continue to build the foundation needed for the expected acceleration in commercial momentum now that our full prime pivotal study results are in hand, which is enabling engaged conversations and increased traction with managed Medicaid and other organizations,” Zhenya Lindgardt, president and CEO, said in announcing the results.
“Furthermore, we plan to share additional compelling data and evidence showing that our PreTRM test can truly make a difference in addressing the impact of premature births while empowering doctors with actionable information to improve pregnancy outcomes and reduce health care costs.”
Lipocine
Lipocine Inc., based in Salt Lake City, reported a net loss of $2.2 million, or 41 cents per share, for the second quarter ended June 30. That compares with a loss of $3.1 million, or 57 cents per share, for the same quarter a year earlier.
The company recognized royalty revenue from TLANDO sales of $123,000 during the quarter, compared with royalty revenue of $90,000 in the year-earlier quarter. License revenue in the most recent quarter totaled $500,000, compared with no license revenue in the comparable period of 2024.
Lipocine is a biopharmaceutical company with a technology platform to develop innovative products with effective oral delivery. It has drug candidates in development as well as some for which it is exploring partnerships.